Cargando…
Microfluidics guided by deep learning for cancer immunotherapy screening
Immunocyte infiltration and cytotoxicity play critical roles in both inflammation and immunotherapy. However, current cancer immunotherapy screening methods overlook the capacity of the T cells to penetrate the tumor stroma, thereby significantly limiting the development of effective treatments for...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674214/ https://www.ncbi.nlm.nih.gov/pubmed/36343225 http://dx.doi.org/10.1073/pnas.2214569119 |
_version_ | 1784833106911428608 |
---|---|
author | Ao, Zheng Cai, Hongwei Wu, Zhuhao Hu, Liya Nunez, Asael Zhou, Zhuolong Liu, Hongcheng Bondesson, Maria Lu, Xiongbin Lu, Xin Dao, Ming Guo, Feng |
author_facet | Ao, Zheng Cai, Hongwei Wu, Zhuhao Hu, Liya Nunez, Asael Zhou, Zhuolong Liu, Hongcheng Bondesson, Maria Lu, Xiongbin Lu, Xin Dao, Ming Guo, Feng |
author_sort | Ao, Zheng |
collection | PubMed |
description | Immunocyte infiltration and cytotoxicity play critical roles in both inflammation and immunotherapy. However, current cancer immunotherapy screening methods overlook the capacity of the T cells to penetrate the tumor stroma, thereby significantly limiting the development of effective treatments for solid tumors. Here, we present an automated high-throughput microfluidic platform for simultaneous tracking of the dynamics of T cell infiltration and cytotoxicity within the 3D tumor cultures with a tunable stromal makeup. By recourse to a clinical tumor-infiltrating lymphocyte (TIL) score analyzer, which is based on a clinical data-driven deep learning method, our platform can evaluate the efficacy of each treatment based on the scoring of T cell infiltration patterns. By screening a drug library using this technology, we identified an epigenetic drug (lysine-specific histone demethylase 1 inhibitor, LSD1i) that effectively promoted T cell tumor infiltration and enhanced treatment efficacy in combination with an immune checkpoint inhibitor (anti-PD1) in vivo. We demonstrated an automated system and strategy for screening immunocyte-solid tumor interactions, enabling the discovery of immuno- and combination therapies. |
format | Online Article Text |
id | pubmed-9674214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | National Academy of Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-96742142023-05-07 Microfluidics guided by deep learning for cancer immunotherapy screening Ao, Zheng Cai, Hongwei Wu, Zhuhao Hu, Liya Nunez, Asael Zhou, Zhuolong Liu, Hongcheng Bondesson, Maria Lu, Xiongbin Lu, Xin Dao, Ming Guo, Feng Proc Natl Acad Sci U S A Physical Sciences Immunocyte infiltration and cytotoxicity play critical roles in both inflammation and immunotherapy. However, current cancer immunotherapy screening methods overlook the capacity of the T cells to penetrate the tumor stroma, thereby significantly limiting the development of effective treatments for solid tumors. Here, we present an automated high-throughput microfluidic platform for simultaneous tracking of the dynamics of T cell infiltration and cytotoxicity within the 3D tumor cultures with a tunable stromal makeup. By recourse to a clinical tumor-infiltrating lymphocyte (TIL) score analyzer, which is based on a clinical data-driven deep learning method, our platform can evaluate the efficacy of each treatment based on the scoring of T cell infiltration patterns. By screening a drug library using this technology, we identified an epigenetic drug (lysine-specific histone demethylase 1 inhibitor, LSD1i) that effectively promoted T cell tumor infiltration and enhanced treatment efficacy in combination with an immune checkpoint inhibitor (anti-PD1) in vivo. We demonstrated an automated system and strategy for screening immunocyte-solid tumor interactions, enabling the discovery of immuno- and combination therapies. National Academy of Sciences 2022-11-07 2022-11-15 /pmc/articles/PMC9674214/ /pubmed/36343225 http://dx.doi.org/10.1073/pnas.2214569119 Text en Copyright © 2022 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/This article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Physical Sciences Ao, Zheng Cai, Hongwei Wu, Zhuhao Hu, Liya Nunez, Asael Zhou, Zhuolong Liu, Hongcheng Bondesson, Maria Lu, Xiongbin Lu, Xin Dao, Ming Guo, Feng Microfluidics guided by deep learning for cancer immunotherapy screening |
title | Microfluidics guided by deep learning for cancer immunotherapy screening |
title_full | Microfluidics guided by deep learning for cancer immunotherapy screening |
title_fullStr | Microfluidics guided by deep learning for cancer immunotherapy screening |
title_full_unstemmed | Microfluidics guided by deep learning for cancer immunotherapy screening |
title_short | Microfluidics guided by deep learning for cancer immunotherapy screening |
title_sort | microfluidics guided by deep learning for cancer immunotherapy screening |
topic | Physical Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674214/ https://www.ncbi.nlm.nih.gov/pubmed/36343225 http://dx.doi.org/10.1073/pnas.2214569119 |
work_keys_str_mv | AT aozheng microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT caihongwei microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT wuzhuhao microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT huliya microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT nunezasael microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT zhouzhuolong microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT liuhongcheng microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT bondessonmaria microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT luxiongbin microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT luxin microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT daoming microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening AT guofeng microfluidicsguidedbydeeplearningforcancerimmunotherapyscreening |